LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
Quantity of Cord Blood under Custody Exceeds 200,000 Units for the First Time in Korea
2015/01/27
CORD BLOOD BANK

MEDIPOST achieved 200,000 units of cord blood under custody for the first time in Korea.

This number is similar to the level under custody by major advanced countries such as U.S. Europe and Japan etc., accounting for 40% of whole domestic cord blood units under custody.

MEDIPOST started cord blood custody service opening Celltree cord blood bank in December 2000, and achieved this grand record in 14 years.

MEDIPOST is keeping the number one market share by widest margin among 17 domestic cord blood banks, in custody of over 15,000 units for recent 3 consecutive years.

MEDIPOST obtained modern facilities such as automatic nitrogen recharge system under central control and internally developed portable cord blood custody tank etc., at its own building located at Pangyo Techno Valley. And remarkably enhanced confidence and stability of cord blood custody.

VIEW LIST

Related News

MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02
Star Actress Choi Jiwoo Stores Her Baby’s Umbilical Cord Blood Unit at MEDIPOST’s CELLTREE2020/05/18
Longer-Term Storage of Cord Blood Gains Popularity Over 20,000 Cumulative Cases at CELLTREE2020/04/29
Korean Star Couple Rain and Kim Tae-hee Bank Baby’s Cord Blood in MEDIPOST2017/10/25

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST